{"id":"W4387114848","doi":"10.3324/haematol.2023.283557","title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"National Cancer Institute; Pharmacyclics; Genentech; F. Hoffmann-La Roche; Incyte; H. Lundbeck A/S; BeiGene; CSL Behring; AstraZeneca; MorphoSys; Celgene; Gilead Sciences; Teva Pharmaceutical Industries; Servier; TG Therapeutics; Amgen","keywords":"Bendamustine; Medicine; Obinutuzumab; Follicular lymphoma; Internal medicine; Tolerability; Rituximab; Adverse effect; Phases of clinical research; Gastroenterology; Lymphoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000286535,0.0004415776,0.001238795,0.0003951081,0.0002831887,0.00003886772,0.0001514827,0.0002296367,0.0002034254],"category_scores_gemma":[0.0003985805,0.0002952772,0.0001477353,0.0009039561,0.0001207469,0.00008475776,0.0002928042,0.0001652536,0.0002419921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007992507,"about_ca_system_score_gemma":0.0004688252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004280135,"about_ca_topic_score_gemma":0.0002144468,"domain_scores_codex":[0.9973322,0.0001430615,0.0006495504,0.0008156116,0.0004281496,0.0006314248],"domain_scores_gemma":[0.9985834,0.0003050959,0.0001649684,0.0006016797,0.0000663,0.0002785027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03130996,0.1450024,0.2552278,0.001689329,0.002915161,0.3695976,0.02765826,0.00007823033,0.001294281,0.003688344,0.03126434,0.1302742],"study_design_scores_gemma":[0.4636967,0.0339385,0.4445263,0.001112149,0.001541506,0.006813007,0.01320007,0.005157713,0.001398124,0.0005107884,0.02646418,0.001640935],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994399,0.001884546,0.000001835973,0.0007312044,0.0001639472,0.001723704,0.00002730377,0.0003876049,0.000680834],"genre_scores_gemma":[0.9977515,0.0003570774,0.0002372224,0.0002640729,0.00005684344,0.0005084445,0.00008236545,0.00004488902,0.0006976355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4323868,"threshold_uncertainty_score":0.9999499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04273158087623399,"score_gpt":0.328386806788105,"score_spread":0.285655225911871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}